News >

Olaparib Approved in Japan for Frontline Maintenance in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Jun 19, 2019

Dave Fredrickson

Dave Fredrickson

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved olaparib (Lynparza) as a maintenance treatment for patients with BRCA-mutant ovarian cancer after undergoing first-line chemotherapy.

The approval was based on findings from the randomized, double-blinded, phase III SOLO-1 study, in which maintenance olaparib significantly improved progression-free survival (PFS) compared with placebo in this patient population following frontline platinum-based chemotherapy.

Olaparib is the sole PARP inhibitor that is approved for use in Japan.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication